On Nov 12, 2025, MGNX reported earnings of 0.27 USD per share (EPS) for Q3 25, beating the estimate of -0.50 USD, resulting in a 153.84% surprise. Revenue reached 72.84 million, compared to an expected 14.99 million, with a 385.79% difference. The market reacted with a +8.84% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.29 USD, with revenue projected to reach 23.10 million USD, implying an decrease of -207.41% EPS, and decrease of -68.29% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abbott Laboratories
Report Date
Jan 22, 2026 For Q4 25
Estimate
$1.51
Actual
$1.50
Surprise
-0.76%
FAQ
What were MacroGenics, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, MacroGenics, Inc. reported EPS of $0.27, beating estimates by 153.84%, and revenue of $72.84M, 385.79% above expectations.
How did the market react to MacroGenics, Inc.'s Q3 2025 earnings?
The stock price moved up 8.84%, changed from $1.47 before the earnings release to $1.60 the day after.
When is MacroGenics, Inc. expected to report next?
The next earning report is scheduled for Feb 19, 2026.
What are the forecasts for MacroGenics, Inc.'s next earnings report?
Based on 9
analysts, MacroGenics, Inc. is expected to report EPS of -$0.29 and revenue of $23.10M for Q4 2025.